Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation by Goede, Jeroen S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2007
Necrobiotic xanthogranuloma successfully treated with autologous stem cell
transplantation
Goede, Jeroen S; Misselwitz, Benjamin; Taverna, Christian; Schanz, Urs; Dispenzieri, Angela; Hummel,
Yvonne; Trüeb, Ralph M; Fehr, Jörg
Abstract: Paraproteinemia can be complicated by necrobiotic xanthogranuloma. Therapeutic options for
this progressive disease are limited, and there is no agreement on a single best strategy. We report the case
of a patient with a massive periorbital infiltration narrowing the palpebral fissure and blinding the patient.
Conventional myeloma therapy had only limited benefit in our patient. However, he was successfully
treated with high-dose chemotherapy followed by autologous stem cell transplantation, rendering the
patient free of symptoms. This is the first report of autologous stem cell transplantation in a patient
with necrobiotic xanthogranuloma
DOI: https://doi.org/10.1007/s00277-006-0231-0
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-155916
Journal Article
Published Version
Originally published at:
Goede, Jeroen S; Misselwitz, Benjamin; Taverna, Christian; Schanz, Urs; Dispenzieri, Angela; Hummel,
Yvonne; Trüeb, Ralph M; Fehr, Jörg (2007). Necrobiotic xanthogranuloma successfully treated with
autologous stem cell transplantation. Annals of Hematology, 86(4):303-306.
DOI: https://doi.org/10.1007/s00277-006-0231-0
LETTER TO THE EDITOR
Necrobiotic xanthogranuloma successfully treated
with autologous stem cell transplantation
Jeroen S. Goede & Benjamin Misselwitz &
Christian Taverna & Urs Schanz & Angela Dispenzieri &
Yvonne Hummel & Ralph M. Trüeb & Jörg Fehr
Received: 17 October 2006 /Accepted: 13 November 2006 / Published online: 11 January 2007
# Springer-Verlag 2007
Abstract Paraproteinemia can be complicated by necro-
biotic xanthogranuloma. Therapeutic options for this
progressive disease are limited, and there is no agreement
on a single best strategy. We report the case of a patient
with a massive periorbital infiltration narrowing the
palpebral fissure and blinding the patient. Conventional
myeloma therapy had only limited benefit in our patient.
However, he was successfully treated with high-dose
chemotherapy followed by autologous stem cell transplan-
tation, rendering the patient free of symptoms. This is the
first report of autologous stem cell transplantation in a
patient with necrobiotic xanthogranuloma.
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Introduction
Necrobiotic xanthogranuloma (NXG) comprises character-
istic xanthomatous skin infiltrates and subcutaneous nod-
ules associated with paraproteinemia. On the skin, yellow,
red-orange or violacious plaques or papules are observed,
typically affecting the periorbital region. With decreasing
frequency, the trunk, face, extremities, buttock and genitalia
can also be involved. The degree of cutaneous manifes-
tations is variable. Some patients are not disturbed at all; in
others, the lesions are disfiguring, cause pain, chronic
ulceration or mechanical complications such as blindness.
Biopsy of cutaneous lesions reveals typical hyaline material
of unknown chemical composition, distributed in a reticular
pattern (necrobiosis). Necrobiosis and cholesterol clefts are
surrounded by foamy macrophages and multinucleated
giant cells (Touton cells). NXG is usually associated with
paraproteinemia of the IgG, less frequently of the IgA class.
In most cases, diagnostic criteria of multiple myeloma are
not met. NXG is a rare condition; it was first described in
1980 [1]; since then, approximately 110 cases have been
published [2, 3]. Treatment is based on myeloma therapy or
follows anecdotal reports; a single best therapy has not been
established [2–7]. We report the first case of successful
autologous peripheral blood stem cell transplantation
(PBSCT) in a patient with NXG.
Case presentation
A 26-year-old man presented to our hematology clinic in
November 2001 with a 12-month history of indurated
yellow palpebral skin infiltrations. Previously, two mono-
typic IgGκ peaks had been recognized on immunofixation
of the serum; however, morphology and percentage of
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plasma cells in the bone marrow were normal. Furthermore,
chronic active hepatitis B with normal liver function tests
and splenomegaly (17 cm) was reported. No therapy was
initiated; the patient was followed closely. One year later,
23 months after the first symptoms, the infiltrates had
progressed. The palpebral fissures were severely narrowed
to a maximum of 3 mm at the left and 2 mm at the right
eye. The patient was unable to work as a lorry driver.
Paraproteinemia had slightly increased (Fig. 1a); the other
hematological parameters had not changed. Biopsy of the
periorbital lesions showed hyaline material with infiltrates
of lymphocytes, plasma cells and foamy macrophages;
necrobiosis was surrounded by giant cells of the Touton
type (Fig. 1b,c). Based on the clinical and pathological
findings, NXG was diagnosed. From October to December
2002, pulsed high-dose oral dexamethasone was applied
[4]. To prevent exacerbation of hepatitis B, lamivudine had
been started previously, which effectively suppressed the
hepatitis B virus (HBV-DNA undetectable by PCR). Within
a few days of dexamethasone treatment, the patient noted
softening of the infiltrates; after several weeks, he was able
to open his eyes. Clinical improvement was accompanied
by a decrease in both M protein peaks (Fig. 1a). However,
three months after the last dexamethasone dose, the
condition relapsed. A trial of thalidomide was not tolerated
by the patient because of severe fatigue. In 2003, para-
proteinemia had progressed; skin infiltrates now also
involved the penis and both nipples. Due to the palpebral
indurations, the patient was now unable to open his eyes
and literally blinded (Fig. 2a). A trial of interferon-α [6]
was ineffective. In November 2003, weekly plasmapheresis
was started [7]. Within a few weeks of treatment, there was
both a decrease in paraprotein and a widening of the
palpebral fissure. However, only 1 month after stopping
plasma exchange, both eyes were occluded again. By
October 2003, the patient was pancytopenic (hemoglobin
12.5 g/dl, thrombocytes 108×109/l, neutrophils 0.84×109/l).
Splenomegaly had progressed to 22 cm. An adrenalin test
[8] proved splenic pooling, prompting splenectomy. Histo-
logical work up showed diffuse infiltration of a low
percentage of plasma cells. Florescence-activated cell
sorting (FACS) analysis of splenic cells identified an IgGκ
plasma cell clone (5% of cells). An IgGκ-clone was also
discovered in the bone marrow, involving 5% of medullar
Fig. 1 a Summary of treatment
and evolution of paraprotein
concentration: Time points for
splenectomy, cyclophosphamide
(CPM) treatment with stem cell
collection and peripheral blood
stem cell transplantation
(PBSCT) are indicated. b Histo-
logical specimen of the right
upper eye lid: low power view
showing hyaline material and a
few giant cells. c: High power
view with foam cells, giant cells
with two and three nuclei and a
multinucleated Touton type gi-
ant cell
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cells; however, repeated microscopic examinations of bone
marrow aspirates were normal with no signs of myeloma.
After splenectomy, the peripheral blood count nearly
normalized. Interestingly, a transient improvement of para-
proteinemia and eye infiltrates was also noted (Figs. 1a and
2b). Because of the severity of the disability, we decided to
proceed to high-dose chemotherapy with PBSCT. Stem
cells were collected using cyclophosphamide mobilization.
The patient was conditioned with melphalan (200 mg/m2)
and dexamethasone in June 2004. A second PBSCT was
declined by the patient. A few weeks after the PBSCT, the
eye infiltrates started to improve (Fig. 2c,d). Cosmetic and
functional recovery was achieved within the next 6 months.
At the time of writing, 26 months after transplantation, the
patient remains free of symptoms (Fig. 3). Paraprotein
concentration had temporarily improved; however, within
the last 14 months, a continuous increase above the level
before transplantation has been observed (Fig. 1a).
Fig. 2 Facial aspect of our
patient. a November 2003: In-
durated palpebral and periorbital
infiltrates. The palpebral fissure
was severely narrowed, causing
mechanical blindness. b April
2004: After splenectomy, the
infiltrates had softened, accom-
panied by improvement of vi-
sion. c June 2004: Further
clinical improvement 2 weeks
after autologous stem cell trans-
plantation. d September 2004:
Three months after transplanta-
tion, the patient had regained
vision
Fig. 3 Facial aspect of our
patient. a In 2002, before treat-
ment. b In 2006, 12 months
after autologous stem cell trans-
plantation. The patient is now
free of symptoms
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Discussion
NXG is a rare complication of paraproteinemia. The chain
of events leading to skin infiltrates in NXG is not
understood. It has been suggested that the paraprotein
binds to lipoproteins. These complexes would be deposited
in the dermis and taken up by histiocytes, leading to foam
cells and a foreign body giant cell reaction [3, 9].
According to another hypothesis, the paraprotein would
directly bind to macrophages inducing activation and
inflammation [10, 11]. No biochemical evidence for either
hypothesis has been presented. In about 20% of all cases,
no monoclonal protein is detectable [1, 2], suggesting that
non-neoplastic antibodies can also trigger the dermal
inflammatory reaction. Without treatment, the skin infil-
trates usually progress; spontaneous remissions are rare.
Survival rates between 45 and 95% have been reported after
10–15 years of follow-up. Most non-survivors had died of
multiple myeloma or apparently non-related neoplasms.
The best therapeutic results have been achieved with
strategies directed against the paraprotein or the neoplastic
B-cell clone producing it. The options reported include
high-dose dexamethasone, anti-myeloma chemotherapy,
plasmapheresis and interferon-α. As in our patient, usually
incomplete or transient relief is achieved by these therapies.
Surgery is considered contra-indicated because ineffective
wound healing can worsen the condition [3]. However, in a
recent report, improvement of palpebral infiltrates was
achieved by skin grafting from a non-affected region [12].
In our patient, PBSCT provided a long-lasting remission.
To our knowledge, this is the first report of PBSCT in a
patient with NXG. Interestingly, in our case, initially two
peaks of an IgGκ paraprotein were detected. During the
course of the disease, changes of peak 1 (closest to the β-
globulins) correlated strongest with palpebral infiltrates.
After PBSCT, peak 1 had disappeared, progression of peak
2 was not accompanied by ophthalmologic complaints
(Fig. 1a), suggesting that these two IgGκ peaks are actually
separate clones rather than monomers and aggregates of M
protein of one clone. It is tempting to speculate that, in our
patient, only peak 1 caused NXG, whereas the more
therapy-resistant peak 2 is not associated with skin
infiltrates. Interestingly, although having pronounced symp-
toms of NXG, the cholesterol level of our patients was very
low (1.9 mmol/l in May 2004), possibly indicating an anti-
lipid activity of the paraprotein. After successful treatment,
cholesterol levels normalized (4.5 mmol/l in August 2006).
In summary, in our patient, autologous stem cell transplan-
tation has been a safe and effective therapy for NXG. Our
data broaden the therapeutic options for patients suffering
from this rare condition and provide further evidence for a
crucial role of the paraprotein in the pathogenesis of this
disease.
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